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ABSTRACT
Tumor-cell-secreted extracellular vesicles (EVs) can cross the disrupted blood-
brain barrier (BBB) into the bloodstream. However, in certain gliomas, the BBB 
remains intact, which might limit EVs release. To evaluate the ability of tumor-derived 
EVs to cross the BBB, we used an orthotopic xenotransplant mouse model of human 
glioma-cancer stem cells featuring an intact BBB. We demonstrated that all types of 
tumor cells-derived EVs−apoptotic bodies, shedding microvesicles and exosomes−
cross the intact BBB and can be detected in the peripheral blood, which provides a 
minimally invasive method for their detection compared to liquid biopsies obtained 
from cerebrospinal fluid (CSF). Furthermore, these EVs can be readily distinguished 
from total murine EVs, since they carry human-specific DNA sequences relevant 
for GBM biology. In a small cohort of glioma patients, we finally demonstrated 
that peripheral blood EVs cargo can be successfully used to detect the presence of 
IDH1G395A, an essential biomarker in the current management of human glioma
INTRODUCTION
Primary malignant brain tumors account for 3% of 
adult cancer deaths and are the second cause of tumoral 
mortality in children [1]. High-grade gliomas are the most 
common primary malignant brain tumors in adults. Despite 
advances in treatment, the median patient survival rate is 12 
to 15 months, as tumor eventually recurs in all patients [2].
Gliomas are commonly detected through clinical 
assessment and imaging techniques. However, the final 
diagnosis relies on the histological analysis of the biopsy 
tissue, in accordance with the WHO current standard 
for glioma diagnostic. Recently published molecular 
pathology-based glioma classification drastically improved 
tumor diagnostics and prognostics, essentially through the 
detection of the IDH1R132H mutation [3, 4].
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With the current treatment protocol, tissue specimens 
are suitable for the evaluation of tumor histopathology at 
the very beginning of the disease, but they do not allow 
molecular evolution assessment of the tumor along the 
course of the disease, which is critical for improving 
patient survival [5]. Thus, the last few years have seen a 
marked increase in using liquid biopsies for monitoring 
cancer genetics, by analyzing circulating cells, nucleic 
acids, or extracellular vesicles (EVs) released from tumors 
[6]. The EVs are present in readily accessible biofluids 
[7–9] and they carry lipids [10], proteins [11], and distinct 
species of nucleic acids [12–14] originating from donor 
cells. According to the Vesiclepedia nomenclature [15], 
three types of EVs can be distinguished: apoptotic bodies 
(ABs), shedding microvesicles (SMVs), and exosomes 
(EXOs). All of these EVs might be useful to identify the 
tumor molecular profile at any time, using minimally 
invasive procedures.
The amount and proportion of these circulating 
tumor-derived EVs might be determined by the integrity 
of the BBB, as well as the tumor size and distribution. 
Recent studies have demonstrated that EXOs administered 
intranasally [16] or injected through the tail vein in mice 
[17] can cross the BBB and deliver their cargo within 
the parenchymal brain, but the barrier’s integrity was not 
discussed in these studies. Therefore, it remains unknown 
whether EVs of glioma cells can cross an intact BBB into 
blood vessels.
Tumoral mutated sequences have been recently 
detected in circulating DNA (ctDNA) and EVs extracted 
from cerebrospinal fluid (CSF) [18, 19]. However, 
CSF extraction through lumbar puncture is an invasive 
procedure and not recommended in patients with high 
intracraneal pressure (commonly present in brain tumors). 
In addition, bearing this in mind, additional efforts to 
develop a blood-based liquid biopsy method for GBM 
patients are required.
To investigate the ability of tumor-derived 
EVs to cross an intact BBB, we used an orthotopic 
xenotransplant model of human cancer stem cells 
(hCSCs), previously described and characterized in 
our laboratory, which produces a disseminated brain-
tumor phenotype featuring an intact BBB [20]. Using 
this model, we showed that all three types of EVs 
derived from human brain tumor cells can cross the 
undisrupted BBB and reach the bloodstream. These 
EVs carried human genomic-DNA (gDNA) sequences 
corresponding to those of the xenotransplanted cells, 
and could be isolated and enriched from peripheral 
blood (Figure 1). In a cohort of glioma patients with 
undisrupted BBB, we demonstrated that peripheral 
blood EV cargo can be successfully used to detect 
Figure 1: Experimental procedure flowchart. A. Isolated hCSCs from 2 GBM patients were xenotransplanted in athymic mice. 
After 12 weeks, the animals were transcardially perfused. B. BBB permeability was evaluated using three assays: MRI, Evans Blue 
staining, and albumin extravasation. C. EVs (ABs, SMVs, and EXOs) were isolated from hCSCs-enriched culture supernatants and from 
mouse peripheral blood. D. EVs were identified using TEM, tracking analysis, and CD63 tetraspanin quantification. E. To ensure that the 
analyzed DNA was confined within the EVs, supernatants and plasma were treated with DNase before gDNA isolation; after the isolation, 
gDNA was pre-amplified before performing PCR analysis with human-specific primers. F. Sequences detected were sequenced to confirm 
their human origin.
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the presence of specific mutations, such as IDH1G395A. 
This finding provides evidence that liquid biopsies can 
successfully improve the current management of brain 
tumors.
RESULTS
GBM xenograft model with intact BBB
Our first aim was to evaluate the capacity of EVs 
secreted by glioma cells to cross normal BBB into the 
bloodstream. For this purpose, we used an orthotopic 
xenotransplant model of hCSCs culture (GBM27), which 
developed an infiltrative brain-tumor phenotype featuring 
an intact BBB in nude mice. We compared this model 
to a second orthotopic xenotransplant model of hCSCs 
culture (GBM38) that generated a nodular brain tumor 
featuring a disrupted BBB in nude mice (Supplementary 
Figure S1). We performed stereotactic transplants of 1 
× 105 cells from GBM27 and GBM38 into the striatum 
of mice. Twelve weeks later we evaluated the functional 
competence of the BBB through 3 distinct procedures 
(Supplementary and Figure S2).
First, we evaluated the BBB integrity in the 
xenotransplant models GBM27 and GBM38 as well as 
in control mice (Figure 2A and Supplementary Figure 
S2A) with MRI images. On GBM38 xenograft tumor, 
we observed an enhancement in T1-weighted images 
with Gadolinium-based contrast agent, a sensitive marker 
of blood-brain barrier disruption (Gd-DTPA-BMA; 
Omniscan, Amersham Health, Oslo, Norway). Conversely, 
no enhancement of Gd-DTPA was observed on the 
GBM27 tumor suggesting an intact BBB. Control mice 
showed no MRI abnormalities.
Figure 2: Evaluation of BBB leakage in two GBM models: GBM27 presents an intact BBB. A. Representative T2- and T1-
weighted images of GBM27 and GBM38. The GBM27 tumor xenotransplant T2-weighted image depicts diffuse hyperintense infiltrative 
involvement. GBM38 xenograft tumor showed well-defined borders. T2-weighted images revealed a hyperintense mass compressing 
ventricular structures. GBM27 features an intact BBB, as revealed by the lack of any contrast enhancement. GBM38 shows a homogeneous 
enhancement, suggesting that the BBB integrity is compromised. B. Evans Blue extravasation. Examination of the brains of perfused 
animals previously stained with Evans Blue confirmed BBB disruption in the GBM38 model. C. Quantification of Evans Blue extravasation. 
*P <0.05. D-E. Immunofluorescence staining of human vimentin (yellow), mouse CD105 (green), and mouse albumin (red). Nuclei were 
stained with DAPI (blue). GBM27 presents no sign of albumin staining throughout the tissue, which indicates that the BBB is intact. 
GBM38 features a leaky BBB, as shown by albumin spreading (white asterisk) from the blood vessels (white arrows) through the tissue. 
Total slides with anti-human vimentin are shown in Fig S1. Scale bar: 50 μm.
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To verify these findings, we visualised and 
quantified the amount of Evans Blue present in the 
parenchymal brain after its injection through the tail 
vein. This test showed that Evans Blue extravasation was 
significantly increased in the mice xenotransplanted with 
GBM38 cells compared to the GBM27 xenotransplanted 
ones (p < 0.05) (Figure 2BC), which confirmed that BBB 
was intact in GBM27 xenotransplants. No Evans Blue 
dye was detected in control brains (Supplementary Figure 
S2B). Finally, to demonstrate the functional competence 
of the BBB, we also analysed albumin extravasation using 
immunofluorescence (Figure 2D and E). Considerable 
albumin diffusion from blood vessels into the parenchymal 
brain of GBM38 xenotransplanted mice was observed 
(Figura 2D). Consistently, no albumin extravasation was 
detected in GBM27 xenotransplants nor in control mice 
(Figure 2 and Supplementary Figure S2D).
Our results confirmed that the GBM27 orthotopic 
xenotransplant model of hCSCs culture displays an intact 
BBB. This allowed us to examine whether tumor-derived 
EVs can cross intact BBB to the bloodstream.
Morphological visualization and size distribution 
of EVs
After demonstrating the suitability of our model, 
we studied whether all three types of EVs could be 
isolated and enriched from hCSCs (GBM27) culture 
supernatant as well as from plasma of xenotransplanted 
mice. EVs were isolated and enriched using 
centrifugation techniques, and then visualized using 
transmission electron microscopy (TEM) (Figure 3A 
and Supplementary Figure S3A). TEM images revealed 
the typical morphology and expected diameter ranges of 
Figure 3: Morphological characterisation of EVs isolated from hCSCs supernatant from GBM27 and gDNA isolation. 
A. Transmission electron microscopy images. ABs (500 nm to 1 μm), SMVs (500–150 nm) and EXOs (150–60 nm). B. Size distribution 
of EVs, as measured using Nanosizer tracking analysis. C. Quantification of the tetraspanin cell-surface glycoprotein CD63. D. Relative 
distribution of EVs. E. Most representative sequences analyzed are present in EVs isolated from GBM27 cells. F. Histogram showing 
the frequency of occurrence of target sequences after 6 consecutive experiments. G. Presence of ERBB2, CDK4, AKT3, and MDM2 
sequences in all types of EVs. The remaining sequences were found randomly in ABs, SMVs, and EXOs. No sequences were detected in 
the supernatant. Scale bars: 1 μm (ABs), 0.2 μm (SMVs and EXOs).
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the ABs (>1 μm), SMVs (~200 nm), and EXOs (~100 
nm). To confirm the enrichment of the different fractions 
of EVs from GBM27 cells, we analyzed them using a 
Zetasizer: the AB fraction ranged from 2000 to 500 nm 
in size, the SMV fraction showed an average size of 
600 nm, and the EXO fraction displayed a main peak at 
180 nm (Figure 3B). The supernatant also showed a small 
10-nm peak, compatible with the presence of proteins. 
These results confirmed the utility of the protocol used to 
isolate EVs from the supernatant. Although these images 
and sizes were consistent with the presence of all three 
types of EVs, we also quantified the relative expression 
of tetraspanin CD63. The results indicated similar CD63 
expression in SMVs and EXOs and a considerably lower 
expression in ABs (Figure 3C). Lastly, EVs distribution 
was quantified using TEM: the EXO fraction was almost 
4 times larger than the AB and SMV fractions in the 
hCSCs supernatant (Figure 3D). A similar trend was 
observed in the case of EVs isolated from mouse plasma 
(Supplementary Figure S3B).
EVs from hCSCs contain gDNA
The presence of human gDNA in EVs was 
verified using a collection of primers specifically 
designed and validated to amplify human gDNA 
sequences (Supplementary Figure S4). We detected 
all the gDNA sequences assayed, except for CDKN2a, 
PTEN, and TP53 sequences (Figure 3E). Then, we 
speculated whether the lack of PCR-amplification of 
these gene sequences might be related to the existence 
of chromosomal aberrations. Accordingly, we examined 
the chromosomal status of GBM27 cells using 
comparative genomic hybridisation (CGH). The CGH 
analysis revealed loss of heterozygosity of chromosome 
9 at p21.3, chromosome 10 at q23.1 and chromosome 
17 at position p13.1, which respectively affect the 
CDKN2a, PTEN and TP53 locations (Supplementary 
Figure S5).
Interestingly, gDNA sequences relevant for the 
GBM biology were detected in all three types of EVs. 
Certain sequences appeared in all EVs, such as ERBB2, 
EGFR, CDK4, AKT3, and MDM2, whereas IDH1 was 
detected only in ABs and EXOs, and a few sequences 
appeared exclusively in one type of EV: PIK3CA, 
MDM4, IDH2, and ASCL1 in ABs, AKT1 in SMVs, and 
MGMT and RB1 in EXOs (Figure 3E-G). Nevertheless, 
we observed a 70,4% frequency of bias in this assay, 
which was independent of our experimental procedure 
(Supplementary Figure S6).
hCSC-derived EVs cross the intact BBB into the 
bloodstream
The GBM27 orthotopic xenotransplant model 
was used to analyze whether all three types of GBM27-
derived EVs can carry relevant human gDNA sequences, 
cross the undisrupted BBB and reach the bloodstream. 
We hypothesised that if this was the case, we should be 
able to detect relevant human gDNA sequences within 
the pool of EVs (both mouse and human) isolated 
from peripheral blood. Thus, we isolated and separated 
all three types of EVs from plasma obtained from the 
inferior vena cava, isolated total DNA from each type 
of EV and performed PCR assays to specifically amplify 
human gDNA sequences. PCR-amplification products of 
the expected sizes were obtained for AKT3 from ABs, 
PIK3CA from ABs and SMVs, and MDM4 and EGFR 
from EXOs. Multiple sequence alignment showed a 
complete homology among these sequences and their 
counterparts from the supernatants of hCSCs-enriched 
cultures (Figure 4).
IDH1G395A gDNA sequences successfully identified 
within EVs isolated from peripheral blood 
of human glioma patients regardless of BBB 
integrity
Having detected tumor-specific gDNA sequences 
within EVs isolated from peripheral blood in a mouse 
model with intact BBB, we next wondered whether 
glioma-derived EVs could be detected in the bloodstream 
of patients, regardless of the BBB integrity. To accomplish 
this, we screened peripheral blood EVs from 21 patients 
(20 diagnosed with low- and high-grade glioma and 1 
brain metastasis) for the presence of IDH1 mutations, 
the most relevant mutation for human glioma diagnostic 
and prognostic [3] (Table 1). To investigate BBB 
integrity, we used the analysis of contrast acquisition 
in T1-weighted images, which takes advantage of the 
incapacity of gadolinium contrast agent to cross the intact 
BBB. In addition, we used Dynamic Contrast-Enhanced 
(DCE) MRI to longitudinally measure the vascular 
constant transfer Ktrans, which reflects BBB permeability 
(Supplementary Figure S7). The results revealed 3 patients 
(HGUGM002, HGUGM003 and HGUGM007) with an 
intact BBB, in contrast to the remaining 18 patients that 
showed a disrupted BBB (Table 1). Next, we assayed for 
the presence of IDH1R132H on surgical solid samples by IHC 
(the Standard of Gold technique) and conventional PCR. 
IHC gave positive results for 3 low-grade (HGUGM003, 
HGUGM007 and HM001) and 1 high-grade (HGUGM008) 
glioma (Table 1). Consistent with these results, IDH1G395A 
was also detected by conventional PCR on these 3 low-
grade glioma samples. Furthermore, this technique detected 
IDH1G395A in an additional low-grade glioma sample 
(HGUGM002), while it was negative for the high-grade 
glioma HGUGM008. Finally, we extracted total DNA from 
EVs from peripheral blood obtained immediately before 
surgery. As a first approach, we used conventional PCR to 
amplify IDH1 gDNA sequences, however, IDH1G395A was 
observed in none of the low-grade gliomas, and only in 4 
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of the high-grade glioma samples, including HGUGM008, 
for which the presence of IDH1R132H was detected on a 
surgical solid sample by IHC (Table 1). Considering these 
results, we hypothesized that IDH1G395A sequences might 
be underrepresented within EVs compared to IDH1wt. To 
solve this problem, we tested the fast ColdPCR technique, 
which, in our hands, is able to enrich and detect IDH1G395A 
when its relative representation is at least as low as 10% 
of total IDH1 sequences (Supplementary Figure S8). We 
used fast ColdPCR on solid samples, for which the results 
were similar to those obtained by conventional PCR. 
Notably, when we used fast ColdPCR on DNA isolated 
Figure 4: Human gDNA sequences are confined inside EVs isolated from xenografted mice. AKT3, MDM4, PIK3CA, and 
EGFR sequences were detected in EVs isolated from the peripheral blood of 10 xenografted mice. The multiple sequence alignment shows 
complete homology among gDNA sequences from GBM27 hCSCs, EVs isolated from hCSCs-enriched culture supernatants, and EVs 
found in mouse peripheral blood. These results confirm the human origin of the sequences. Keyword: GBM1= GBM27.
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from peripheral blood EVs, we detected the presence of 
IDH1G395A in 47.6% of the samples included in the cohort. 
Within the low-grade gliomas, IDH1G395A was identified in 
80% of the samples, matching our previous results from 
IHC and conventional PCR on solid samples. Interestingly, 
within high-grade gliomas, we also detected IDH1G395A in 
40% of the samples, including those previously detected 
by conventional PCR. The same technique identified only 
IDH1wt on DNA isolated from peripheral blood EVs of a 
patient diagnosed with adenocarcinoma brain metastasis, 
used as a negative control.
These results support the idea that EVs secreted 
by brain tumor cells can cross the BBB, whether intact 
or disrupted, and enters the bloodstream. Therefore, the 
analysis of their cargo might be useful as a biomarker 
not only for high-grade gliomas but also for low-grade 
gliomas, most of which conserve an intact BBB.
DISCUSSION
The BBB maintains the brain environment and 
protects it against external factors. In glioma-diagnosed 
patients and xenografted mice, the BBB dysfunction 
is partially due to the impairment of tight junctions, 
which explains the fluid leakage and cerebral oedema 
associated with these tumors [21, 22]. However, a 
completely functional BBB is occasionally found in 
orthotopic xenograft mouse models [23], in certain low-
grade human gliomas and a few high-grade gliomas 
[24]. In agreement with these reports, we demonstrated 
that the GBM27 orthotopic xenotransplant mouse 
model of hCSCs culture displays a functional BBB, 
using three approaches: Gd-DTPA MRI, external tracer 
Evans Blue, and evaluation of albumin extravasation by 
immunofluorescence. Thus, using the GBM27 model, 
we are able to assess the potential presence of brain 
tumor EVs in peripheral blood after crossing the intact 
BBB.
We have shown that gDNA sequences are present 
inside all three types of EVs isolated from the hCSCs 
supernatant. Other groups have also demonstrated the 
presence of gDNA sequences within total and fractioned 
EVs [13, 25].
Interestingly, we noted a key variability in the 
detection of specific gDNA sequences in the EVs, and 
based also on previous reports [26], we hypothesised that 
this variability might be more related to the representation 
of such sequences within the cell of origin than to the 
isolation and pre-amplification procedures. Although 
analysing the gDNA sequences contained within all three 
types of EVs might be useful for obtaining clinically 
relevant information, our results raise at least two 
technical issues. Firstly, the amount of tumor-derived EVs 
within the total pool of circulating EVs is relatively low. 
Secondly, the relative presence of mutated gDNA versus 
wild type sequences within tumor-derived EVs cargo is 
questionable. Further investigation is therefore required to 
elucidate the mechanisms underlying nucleic acid uptake 
by EVs.
Another critical factor that must be addressed in 
order to assess the use of EVs as biomarkers is the ability 
to separate EVs secreted by tumor cells from the total EVs 
pool. Here, we have shown that orthotopic xenotransplant 
animal models of human tumor cells are suitable models 
for providing ‘proof of concepts’ related to the utility of 
specific molecular biomarkers present within EVs.
The presence of circulating EVs secreted from 
glioma cells has been strongly correlated with tumor size 
and the BBB status [27]. Here, we demonstrated for the 
first time that human gDNA sequences relevant for the 
GBM biology can be detected within all three types of 
EVs isolated from the bloodstream of tumor-bearing mice. 
In this context, some groups have recently postulated the 
use of CSF as a source of tumor-derived DNA sequences 
[19, 21]. However, the lumbar puncture is often unfeasible 
in glioma patients mostly due to the high intracranial 
pressure [28].
Notably, our findings confirm that not only tumor-
secreted EXOs but also ABs and SMVs can cross the intact 
BBB into the bloodstream. This is essential to standardize 
the use of circulating EVs in serum as glioma biomarkers 
regardless of the BBB status, providing a minimally 
invasive method compared to CSF. However, the exact 
mechanism used by EVs to cross the BBB remains elusive 
and might differ depending on the EV type.
Finally, the new molecular pathology-based 
classification of gliomas expanded current molecular 
knowledge about prognostic and diagnostic implications 
of a variety of biomarkers used to characterize glioma 
patients. For example, IDH1-mutated patients are 
expected to have longer survival rates than their wild-
type counterparts despite similar histopathologic features 
[29]. Moreover, immunotherapy is a field of growing 
interest in brain oncology and specific glioma hallmarks 
are considered as immuno-targets. In this regard, a few 
IDH1 peptide vaccines trials are currently going on [30]. 
Unfortunately, there are obvious limitations to obtain a 
representative glioma tissue sample. This restrains the 
access to new therapies and clinical trials and impairs 
monitoring of drug resistance and/or clonal dynamics 
during treatment. As a consequence, almost all clinical 
trials accept first biopsies as a tissue to assess IDH1R132H 
or any other target status. In this context, we addressed 
the potential use of tumor-derived EVs cargo in serum 
isolated from high or low grade brain tumor patients by 
looking for the presence of IDH1G395A, currently the most 
valuable molecular marker for human glioma diagnostics 
and prognostics [3]. In our hands, conventional PCR was 
useful to detect the wild type form, but unable to reveal the 
mutated form of IDH1 in DNA sequences from peripheral 
blood EVs, which might explain why previous works also 
reported negative results [19, 21]. Here, we demonstrated 
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for the first time, that fast Cold-PCR can be successfully 
used to enrich the mutated form of IDH1 in DNA 
sequences from peripheral blood EVs isolated from brain 
tumor patients. In our cohort, the results obtained from 
liquid biopsies were consistent with those observed from 
solid samples of low-grade gliomas, but not with high-
grade gliomas. The higher number of positive IDH1G395A 
observed in high-grade gliomas, as compared with their 
corresponding solid samples, might be explained by the 
intra-tumor heterogeneity, for the small specimen analyzed 
by pathological anatomy barely represents the whole 
tumor. However, additional studies with larger cohorts 
are needed to consolidate and validate the use of DNA 
sequences isolated from the peripheral blood EVs of brain 
tumor patients.
In conclusion, we have demonstrated that all 
three types of EVs secreted by human glioma cells can 
cross the intact BBB. Furthermore, we prove that DNA 
sequences from peripheral blood EVs isolated from 
brain tumor patients can be successfully used to detect 
the presence or absence of specific molecular alterations 
such as IDH1G395A. This finding supports, for the first time, 
the utility of tumor-derived DNA within all three types 
of circulating EVs as potential biomarkers to improve 
Table 1: IDH1G395A gDNA sequence identification in liquid biopsies from human glioma patients with or without BBB disruption
Patient ID Patient 
variables
Pathological anatomy BBB integrity evaluation by 
MRI-based techniques
Surgical sample analysis Liquid biopsy analysis
Sex Age Pathologic
 diagnosis
Grade BBB 
integrity
Contrast 
acquisition
Ktrans 
(10-3/
min)
IHQ FFPE 
Conventional 
PCR
FFPE Fast 
COLDPCR 
EVs 
Conventional 
PCR
EVs Fast 
ColdPCR
HGUGM002 F 63 Oligodendro 
glioma
II No 
disrupted
No 0 WT G395A G395A N/D G395A
HGUGM003 M 33 Oligodendro 
glioma
II No 
disrupted
No 10 R132H G395A G395A WT G395A
HGUGM007 F 48 Oligoastro 
cytoma
II No 
disrupted
No N/D R132H G395A G395A N/D G395A
HM001 M 31 Astrocytoma II Disrupted Yes N/D R132H G395A G395A WT G395A
HM012 M 56 Astrocytoma II Disrupted Yes N/D WT WT WT N/D WT
HM009 M 56 Astrocytoma III Disrupted Yes N/D WT WT WT WT WT
HGUGM004 M 47 Grade III 
Astrocytoma 
with grade IV 
areas
IV Disrupted Yes 184-
427
WT WT WT N/D WT
HGUGM005 F 43 Giant-Cells  
GBM
IV Disrupted Yes N/D WT WT WT G395A G395A
HGUGM006 M 53 GBM IV Disrupted Yes N/D WT WT WT WT G395A
HGUGM008 M 39 GBM, recurrence IV Disrupted Yes N/D R132H WT WT G395A G395A
HGUGM009 F 64 GBM, recurrence IV Disrupted Yes N/D WT WT WT N/D WT
HM002 M 42 GBM IV Disrupted Yes N/D WT WT WT WT WT
HM003 F 61 GBM IV Disrupted Yes N/D WT WT WT G395A G395A
HM004 M 65 GBM IV Disrupted Yes N/D WT WT WT WT WT
HM005 F 36 GBM IV Disrupted Yes N/D WT WT WT WT WT
HM006 M 48 GBM IV Disrupted Yes N/D WT WT WT G395A G395A
HM007 F 66 GBM IV Disrupted Yes N/D WT WT WT N/D G395A
HM008 F 65 GBM IV Disrupted Yes N/D WT WT WT N/D WT
HM010 M 43 GBM IV Disrupted Yes N/D WT WT WT N/D WT
HM011 F 61 GBM IV Disrupted Yes N/D WT WT WT WT WT
HGUGM001 F 61 Adenocarcinoma 
Brain metastases
O Disrupted Yes 638 WT WT WT WT WT
Samples are organized by tumor grade. BBB integrity is evaluated mainly by contrast acquisition, but also by Ktrans when possible. Surgical tumor tissues 
were analyzed by IHQ, conventional PCR and Fast Cold PCR. Liquid biopsies were analyzed mainly by Fast Cold PCR. Keywords: BBB, blood brain 
barrier and N/D, not determined.
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diagnostics, prognostics and follow-up for both low- and 
high-grade gliomas.
MATERIALS AND METHODS
Human samples and derivation of glioblastoma-
cancer stem cells-enriched cultures
Two tumor samples from GBM patients (GBM27 
and GBM38) were processed within 12 h after extraction 
according to the protocol described previously [31]. 
Briefly, the samples were minced and washed in Ca2+/
Mg2+-free HBSS (Hanks balanced salt solution). 
Enzymatic digestion was sequentially performed with 
Solution I (papain (14 U ml-1, Sigma-Aldrich) and DNase 
I (10 U ml-1, Sigma) in PIPES solution) for 90 min at 
37°C and Solution II (papain (7 U ml-1) and DNase I (15 
U ml-1) in 1:1 PIPES: proliferation medium) for 30 min 
at 37°C. The cells were then dissociated using diameter-
tapering polished Pasteur pipettes, filtered through a 
70-μm mesh, and resuspended in defined proliferative 
media. These CSCs lines were previously described and 
characterized in detail by our laboratory [20].
Solid surgical tissue samples and peripheralblood 
were obtained from patients operated at HM Hospitales 
(HM), Madrid, Spain; Hospital Universitario la Fe 
(HUlaFe), Valencia Sapin and Hospital General 
Universitario Gregorio Marañón (HGUGM), Madrid, 
Spain. Peripheralblood samples from patients were 
collected prior to surgery. These blood samples were left 
to clot for 30 min at room temperature and serum was 
isolated and stored at -80°C until use.
Xenotransplants
Approximately 105 cells from 2 cancer-stem cell 
cultures (GBM27 and GBM38) were injected into the right 
striatum of 10 immunosuppressed athymic nude female 
mice by using a stereotactic device. As a negative control, 
PBS was injected into 2 mice following the same protocol. 
Twelve weeks post-injection, mice were anaesthetised 
and then transcardially perfused with saline and prefixed 
with 4% paraformaldehyde. The brains were post-fixed 
for 48 h after the infusion and embedded in paraffin, after 
which 3-μm coronal sections were obtained.
Magnetic resonance imaging (MRI) in mice
Magnetic resonance experiments were performed 
on a 7.0-T Bruker Pharmascan (Bruker Medical Gmbh, 
Ettlingen, Germany) superconducting magnet, with 
Paravision 5.1 software. T2-weighted MRI and T1-
weighted MRI after paramagnetic contrast-agent 
administration were used to assess tumor implantation and 
BBB integrity, at time 0 and at 90 days. Prior to scanning, 
mice were anaesthetised with isofluorane.
T2-weighted images were acquired by using the 
rapid acquisition with refocused echo (RARE) sequence 
with the following parameters: TR/TE (repetition time/
echo time) = 2500/44 ms, field of view = 2.3 cm, 6 averages, 
matrix size = 256 × 256, number of slices = 14, and slice 
thickness = 1 mm without a gap. The total scan time required 
to concurrently acquire T2-weighted images was 6 min.
Subsequently, we modified certain parameters for 
T1-weighted images; for example, we used the multi-
slice multi-echo (MSME) sequence, TR/TE = 3500/10.6 
ms, 3 averages, and total time of acquisition = 3 min 2 s. 
The contrast agent used, 0.3 M Gd-DTPA, was injected 
intraperitoneally.
Evans blue injection and brain extraction
A 2% Evans Blue dye solution (Sigma-Aldrich) 
was administered (2 ml kg-1) through the tail vein and, 
1 h later, the mice were transcardially perfused and the 
brains were extracted, weighed, and homogenised using 
a TissueLyser LT (Qiagen) in twice their volume of 
N,N-dimethylformamide (Sigma-Aldrich). The tissues 
were incubated overnight at 55°C and then centrifuged 
for 20 min at 9300 × g. The optical density (OD) of the 
supernatant was measured at 610–635 nm, and the amount 
of Evans Blue extravasation was quantified as nanograms 
per milligram of tissue.
Immunofluorescence staining
Immunofluorescence staining for mouse albumin 
was performed to determine the vascular integrity of the 
brain. Brain sections obtained from GBM27 and GBM38 
hCSCs and PBS control xenotransplants were incubated 
with a 5% blocking solution of the specific serum, and 
then incubated (overnight, 4°C) in solutions containing 
the following primary antibodies: goat anti-mouse CD105 
(R&D Systems), goat anti-mouse albumin (Santa Cruz 
Biotechnology), and mouse anti-human vimentin (Santa 
Cruz Biotechnology). Then, Alexa Fluor-conjugated 
secondary antibodies were used for 1 h (donkey anti-goat 
568, rabbit anti-goat 488, and goat anti-mouse 660; Life 
Technologies, USA), and then nuclei were counterstained 
with DAPI and coverslips were mounted using FluorSave™ 
reagent (Millipore). Fluorescence was examined under a 
Leica TCS SP5 inverted confocal microscope.
Immunohistochemistry
Formalin-fixed paraffin-embedded sections were 
stained (as per the manufacturer’s staining protocol) with 
the Bond Polymer Refine Detection Kit on a Bond-max™ 
fully automated staining system (Leica Microsystems 
GmbH, Germany), using a mouse monoclonal antibody 
against human IDH1R132H (Clon H09, Dianova) for the 
detection of mutant IDH1R132H.
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Mice plasma samples
Twelve weeks after the xenotransplantation, mouse 
peripheral blood was collected from the inferior vena 
cava, and centrifuged at 1500 × g for 10 min to obtain the 
plasma.
Extracellular vesicles isolation
EVs from plasma and serum samples and cell 
medium supernatants were isolated through differential 
ultracentrifugation as previously described [32], with 
certain modifications. Briefly, to remove cellular debris, 
samples were centrifuged at 1200 × g for 5 min. The 
supernatant was carefully aspirated off without disturbing 
the pellet and centrifuged at 8000 × g for 20 min to obtain 
ABs. Next, this supernatant was centrifuged at 25,000 
× g for 20 min to obtain SMVs, and then the remaining 
supernatant was ultracentrifuged at 117,000 × g for 90 
min to obtain EXOs (Optima-LE 80K ultracentrifuge, 
50.2 Ti rotor; Beckman Coulter). All centrifugations were 
performed at 4°C. A sample of the EVs-free supernatant 
was collected after the ultracentrifugation and used as a 
negative control. In samples from human, total EVs were 
analyzed. Samples were immediately used or stored at 
-20°C.
Transmission electron microscopy
EVs samples were individually added onto glow-
discharged 150-mesh formvar copper grids (EMS™), 
subjected to the glow-discharge procedure (2 min, 2.4 
MA), and then incubated for 2 min at 4°C. The grids 
were washed, negatively stained with 2% aqueous uranyl 
acetate solution, dried, and analyzed by performing TEM 
(FEI Tecnai Spirit G2 and Tecnai 12) at 80 kV. EVs were 
classified based on their size, photographed, and counted 
using a Soft Image System Morada camera.
Tracking analysis
Mean droplet sizes of EVs were measured using the 
dynamic light scattering method and a Zetasizer Nano ZS 
(Malvern Instruments, UK).
Flow-cytometry analysis of CD63 expression
AB, SMV, or EXO samples were adsorbed onto 
4-mm aldehyde/sulphate latex beads (Invitrogen, Paisley, 
UK) overnight at 4°C. The reaction was stopped by adding 
glycine 100 mM. Membrane-bound beads were washed in 
PBS/1% BSA, incubated with mouse anti-CD63 (Abcam, 
Cambridge, UK) or appropriate isotype control for 30 min 
at 4°C, stained with FITC-conjugated secondary antibody 
(R&D Systems) for 30 min at 4°C, and resuspended in 0.5 ml 
of PBS. Samples were analyzed using a FACS Calibur flow 
cytometer (BD Biosciences, San Jose, CA, USA).
DNA isolation and pre-amplification and PCR
Formalin-fixed paraffin-embedded (FFPE) samples 
were deparaffinized and extracted using the DNeasy Blood 
& Tissue Kit spin columns according to the manufacter´s 
protocol. (Qiagen, Germany). Before DNA isolation, 
supernatant and plasma samples were treated with 27 
Kunitz U ml-1 of DNase I (Qiagen) for 30 min at 37°C 
to remove potential free-DNA contaminants. Total DNA 
was extracted from EVs and cells by using a DNeasy 
Blood and Tissue Kit (Qiagen), as per manufacturer 
recommendations. Next, a working solution of the 
extracted DNA was pre-amplified using the GenomePlex 
Complete WGA2 Kit (Sigma-Aldrich), according to the 
manufacturer’s instructions. All PCRs were performed 
following the protocol of the Paq5000 enzyme (Agilent 
Technologies) (Supplementary Figure S8B). The final 
PCR products were electrophoretically separated on 1.8% 
agarose gels.
Fast Cold-PCR
For the enrichment and detection of IDH1 mutated 
gDNA sequences within EVs isolated from peripheral blood 
of human patients, DNA was amplified using the reported 
primers: forward 5’- CGGTCTTCAGAGAAGCCATT-3’ 
and reverse 5’-GCAAAATCACATTATTGCCAAC-3’ 
[33] (Supplementary Figure S8A). Cycling conditions 
were as follows: a first denaturation step of 10 min at 96ºC, 
followed by a set of 20 cycles of 96ºC for 15 sec and 60ºC 
for 15 sec, and a second set of 30 cycles of 15 sec at Tc 
(critical temperature) and 60ºC for 15 sec (Supplementary 
Figure S8C).
Sequencing and assembly
DNA sequencing of the PCR-amplified products of 
AKT3, EGFR, MDM4, PIK3CA and IDH1 was performed 
by the sequencing service at Spanish National Cancer 
Research Center (CNIO). Sequences were compared 
and aligned using the BLAST algorithm and CLUSTAL 
Omega, respectively.
Dynamic contrast enhanced (DCE)-MRI data 
acquisition and analysis
Preoperative MR images were obtained using a 1.5 
T MRI scanner (Achieva of Intera, Philips Healthcar, Best, 
The Netherlands) and 8-channel SENSE head coil. For 
DCE-MRI, baseline 3D T1-weighted images were obtained 
with the following parameters: TR 76 ms, TE 3ms, slice 
thickness 5mm, Field of View (FOV) 230 mm, matrix size 
of 116 x128, 35 volumes, temporal resolution 5,4 s and flip-
angles of 5º and 15º to create two precontrast datasets. Then, 
a DCE perfusion imaging dynamic series was performed 
using T1-weigthed sequences with the same MR parameters 
except for an increased flip angle of 15º. At the end of the 
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second volume acquisition, a bolus of 14 ml of gadobenate 
dimeglumine (Multihance, Bracco Imaging, Spain) was 
injected intravenously at a rate of 3-4 ml/s.
Structural contrast 3D T1 fast field echo (FFE) 
sequence was performed and the detail parameters were 
as follows: TR/TE= 4,6/9,4 ms, flip angle 8º, FOV 256 
× 256 mm, matrix size 256x 256 and reconstructed voxel 
size of 1 × 1 × 1mm.
To observe BBB permeability, vascular constant 
transfer (Ktrans min-1) values were calculated using 
Philips IntelliSpace Portal v.6 Software by simultaneous 
observation of axial postcontrast T1-weigthed images and 
corresponding colour parametric Ktrans maps. One region of 
interest was manually positioned on the solid tumoral area.
Statistics
Statistical analysis were performed using a 2-tailed 
Student t test. Data are presented as means ± standard 
deviation and were calculated using the software package 
GraphPad Prism v. 5.0. Statistical values of p > 0.05 were 
not considered significant.
Study approval
Procedures used on mice were approved by and 
performed according to the guidelines of the institutional 
animal-care committee of the Principe Felipe Research 
Center in agreement with the European Union and 
National directives. Permission to use human samples was 
obtained from the ethical review board in HM Hospitales, 
Hospital Universitario la Fe, Valencia, and Hospital 
General Universitario Gregorio Marañón, Madrid and 
written informed consent was obtained from patients.
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